

## TEST UPDATE: CYSTIC FIBROSIS CARRIER SCREENING NEW TEST OFFERING

**Pranil K. Chandra, DO**, Vice President and Medical Director, Molecular Pathology Services  
**Scott Wheeler, PhD, FACMG**, Associate Director, Molecular Diagnostics

**October 17, 2017**

**Effective today, October 17, 2017**, PathGroup offers a new test for **Cystic Fibrosis (CF) Carrier Screening**. In our effort to provide the most innovative and clinically applicable tests available, this new test includes 175 clinically relevant *CFTR* mutations, which improves the *CFTR* mutation detection rate across all ethnicities, particularly African Americans and Hispanic Americans. Professional medical organizations, including ACOG, *recommend CF carrier screening be offered to all patients*.<sup>1</sup>

Ethnic Group	Detection Rate	
	ACMG/ACOG Recommended Panel (23 mutations)	PathGroup Test Code CFSCRN (175 mutations)
Ashkenazi Jewish	94%	96%
Caucasian	88%	92%
African American	64%	78%
Hispanic	71%	84%
Asian American	49%	55%

For a full listing of the mutations included in this new expanded CF panel, visit <https://www.testmenu.com/PathGroup/Tests/845530>.

The new test (Test Code: CFSCRN) will **replace** the previous test (Test Code: CF44), providing a higher level of service, but the test specifications and pricing will remain the same. No action is required of PathGroup accounts or providers. Orders for Test Code CF44 will automatically transition to Test Code CFSCRN effective October 17, 2017. CF44 will **no longer be available**.

### **Test Specifications:**

**Test Name:** Cystic Fibrosis (CF) Mutation Detection  
**Test Code:** **CFSCRN**  
**Specimen Type:** Whole Blood  
**Specimen Volume:** 4mL whole blood  
**Specimen Container:** EDTA (lavender) tube preferred; ACD solution (yellow) tube accepted  
**Specimen Transport:** Room temperature preferred; Refrigerated accepted  
**Turnaround Time:** 5-7 days

*Note: Pre-authorization is required by some insurance payers. Please consult patient's insurance payer.*

**For more information, contact your local PathGroup representative or  
PathGroup Client Services at 1-888-474-5227.**

<sup>1</sup>"It is important that CF screening continues to be offered to women of reproductive age. It is becoming increasingly difficult to assign a single ethnicity to individuals. It is reasonable, therefore, to offer CF carrier screening to all patients." – ACOG Cmte Opinion No. 486, April 2011.